trending Market Intelligence /marketintelligence/en/news-insights/trending/01VsDMGtLok3wqiCe4xbqQ2 content esgSubNav
In This List

Verrica files for US FDA approval of contagious skin disease therapy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Verrica files for US FDA approval of contagious skin disease therapy

Verrica Pharmaceuticals Inc. filed an application with the U.S. Food and Drug Administration seeking approval for its medicine VP-102 to treat a type of contagious skin disease.

The West Chester, Pa.-based medical dermatology company is studying VP-102 to treat molluscum contagiosum — an infection caused by a poxvirus that results in round, firm, painless bumps on the skin. The condition affects about six million people in the U.S., primarily children. There is no FDA-approved treatment for molluscum, the company said in a Sept. 16 press release.

The application was backed by positive data from two phase 3 trials, which showed that the drug helped achieve clearance of lesions on the skin.

VP-102 is also being evaluated by Verrica to treat verruca vulgaris, or common warts.